Affordable Access

[HCV protease inhibitors and drug resistance].

Authors
  • Pawłowska, Małgorzata
  • Olczak, Anita
Type
Published Article
Journal
Przegla̧d epidemiologiczny
Publication Date
Jan 01, 2012
Volume
66
Issue
1
Pages
55–57
Identifiers
PMID: 22708299
Source
Medline
License
Unknown

Abstract

Treatment efficacy ofDAAs is limited in the presence of HCV mutants which revealed amino-acids substitution and drug resistance. Because of the high genetic heterogeneity of HCV and its rapid replication, monotherapy with DAA agents poses a high risk for selection of resistant variants. We review the factors that determine resistance, the methods of resistance detection and strategies to avoid the selection of resistant variants.

Report this publication

Statistics

Seen <100 times